Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint

Daiichi Sankyo has reported that the Phase I/II/III clinical trial of a messenger ribonucleic acid (mRNA) vaccine for Covid-19, DS-5670, as a booster met the primary endpoint.

The trial analysed the safety and efficacy of the booster dose of DS-5670.